News Releases

Jan 28, 2015
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February

REDWOOD CITY, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced its participation at two investor conferences during the month of February.

BIO CEO and Investor Conference

On Monday, February 9, 2015, Paul Hastings, OncoMed's Chairman and Chief Executive Officer, will present a corporate update at 11:30 am EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.

2015 Leerink Global Healthcare Conference

On Thursday, February 12, 2015, Mr. Hastings will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 8:05 a.m. EST.

These presentations will be webcast live and available for replay for up to 60 days from the OncoMed website in the Investor Relations section.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

CONTACT: Media & Investors

         OncoMed Pharmaceuticals

         Michelle Corral

         Investor Relations and Corporate Communications

         michelle.corral@oncomed.com

         (650) 995-8373

         

         Investors

         Shari Annes

         Annes Associates

         shari.annes@oncomed.com

         (650) 888-0902

OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site www.mereobiopharma.com for our Pipeline, Partnering Opportunities and Investors information.